IFNA17 and synovial sarcoma: The first-line systemic therapy of advanced-stage CTCL or SS is still based on immune response modifiers, including interferon-alpha (IFNα), low-dose methotrexate (LD-MTX), or bexarotene (12–14); these can also be used as a maintenance therapy after total skin electron beam therapy (15).